A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Abstract

BACKGROUND:

Some reports have pointed out that calcimimetics agents are effective in the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, but there is no detailed description of the advantages and disadvantages of calcimimetics agents of SHPT in CKD patients. We tried to pool the published data to verify the effectiveness of calcimimetics agents and to compare the advantages and disadvantages of cinacalcet compared with control in the treatment of SHPT in CKD patients.

METHODS:

We included eligible studies of published papers from January 1st, 2000 to December 31st, 2020 in Medline, Pubmed and Web of science databases, and the data were extracted for this meta-analysis.

RESULTS:

Twenty-seven studies were eligible, and all the included studies were randomized controlled trials (RCT) including patients treated with long-term dialysis. The results indicated that calcimimetic agents can reduce the parathyroid hormone (PTH, pg/ml) level (WMD = -178.22, 95% CI: -238.57, -117.86, P < 0.00001), calcium (Ca, mg/dl) level (WMD = -0.71, 95% CI: -0.86, -0.55, P < 0.00001), phosphorus (P, mg/dl) level (WMD = -0.32, 95% CI: -0.55, -0.08, P = 0.008), calcium-phosphorus product level (WMD = -7.73, 95% CI: -9.64, -5.82, P < 0.00001). Calcimimetic agents increased the bone alkaline phosphatase (BSAP, ng/ml) levels and rate of achieving target PTH, and reduced osteocalcin levels and the rate of parathyroidectomy. Calcimimetic agents increased the total adverse events' rate, the rate of hypocalcemia and gastrointestinal side effects (nausea, vomiting, abdominal pain and diarrhea), but there was no significant difference in serious adverse events between the calcimimetic agent group and control group.

CONCLUSION:

Calcimimetic agents can reduce the PTH level, Ca level, P level, calcium-phosphorus product level and do not increase serious adverse events.

• Authors: Yiping Liu, Qian Yang, Guangyong Chen, Tianbiao Zhou
• Journal: Current pharmaceutical design (Curr Pharm Des) Vol. 28 Issue 40 Pg. 3289-3304 ( 2022) ISSN: 1873-4286 [Electronic] United Arab Emirates
• PMID: 36305135 (Publication Type: Systematic Review, Meta-Analysis)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Calcimimetic Agents
• Calcium
• Naphthalenes
• Parathyroid Hormone
• Phosphorus

Topics

• Humans
• Calcimimetic Agents (adverse effects)
• Calcium
• Naphthalenes (adverse effects)
• Hyperparathyroidism, Secondary (drug therapy, chemically induced)
• Parathyroid Hormone
• Renal Insufficiency, Chronic (complications, drug therapy)
• Phosphorus (therapeutic use)
• Randomized Controlled Trials as Topic